Company / Operating Cash Flow
ADMA Biologics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$50.4M
FY2025
5-year range
-$112.4M / $118.7M
FY2021-FY2025
Trend
-57.5%
vs FY2024
Sector context
#60 of 216
Health Care
What the data says
At $50M, ADMA Biologics, Inc.'s operating cash flow ranks #60 of 216 in the Health Care sector. Improved from $9M to $50M over the past 2 years.
Based on SEC 10-K filings.
$50M in FY2025.
Improved from $9M to $50M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#60 of 216 in Health CareTop 28% of 216This company $50.4M Sector average $659.0M
▼
-92.4% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 57.5% year-over-year.
- Ranks #60 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.4M | -57.5% |
| FY2024 | $118.7M | +1248.5% |
| FY2023 | $8.8M | +107.8% |
| FY2022 | -$112.4M | +0.0% |
| FY2021 | -$112.4M | -10.2% |
| FY2020 | -$102.0M | -33.9% |
| FY2019 | -$76.2M | -21.6% |
| FY2018 | -$62.7M | -243.1% |
| FY2017 | -$18.3M | +0.0% |
| FY2016 | -$18.3M | -24.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026